NOXXON publishes a shareholder letter
(WorldNews Germany)

NOXXON PUBLISHES A SHAREHOLDER LETTER Berlin, Germany, February 18, 2019, 08.00 a.m. CET - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), published today a shareholder letter addressing recent clinical data and outlining its corporate strategy going forward. The letter is available in the annex to this press release and on the NOXXON website at For more information, please contact: NOXXON Pharma N.V. Aram Mangasarian, Ph.D., Chief Executive Officer Tel. +49 (0) 30 726247 0amangasarian@noxxon.com MC Services AG Raimund Gabriel, Managing Partner Tel. +49 (0) 89 210228...